Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 9/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RPA1 | P27694 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17522579 | 0.83 | BAZ2B (0.40) | KDM4EGRNSORT1BAZ2BALDH1A1 | |
| SCHEMBL4751927 | 0.81 | PLA2G10 (0.49) | KDM4EBAZ2BALDH1A1POLB | |
| SCHEMBL222289 | 0.78 | BAZ2B (0.63) | HCAR2DAOKDM4EGRNSORT1 | |
| SCHEMBL70171 | 0.78 | KDM4E (0.58) | HCAR2HCAR3DAOKDM4EGRN | |
| SCHEMBL537448 | 0.78 | MALT1 (0.41) | KDM4EGRNSORT1BAZ2BALDH1A1 | |
| SCHEMBL295558 | 0.78 | MAPK1 (0.42) | KDM4EBAZ2BALDH1A1POLBGAA | |
| SCHEMBL5879683 | 0.77 | KDM4E (0.39) | HCAR2DAOKDM4EGRNSORT1 | |
| SCHEMBL22235052 | 0.77 | KDM4E (0.39) | HCAR2DAOKDM4EGRNSORT1 | |
| SCHEMBL1313309 | 0.77 | KDM4E (0.39) | HCAR2DAOKDM4EGRNSORT1 | |
| SCHEMBL16468579 | 0.77 | RPA1 (0.40) | KDM4EGRNSORT1BAZ2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024153155-A1 | DOUBLE-HETEROCYCLIC WRN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都微芯药业有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11174219-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021203025-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| CN-112979550-A | Method for preparing 1-methyl-5-hydroxypyrazole by using microchannel reactor | 山东亿盛实业股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10829438-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-10315984-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-06-11 | — | — | US | disclosed |
| WO-2008047071-A1 | TRISAZO-DYES WITH A PYRAZOLYL END GROUP AND THEIR USE IN INK-JET PRINTING | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047071-A1 | TRISAZO-DYES WITH A PYRAZOLYL END GROUP AND THEIR USE IN INK-JET PRINTING | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| EP-1131299-B1 | METHOD FOR PRODUCING 1-SUBSTITUTED 5- OR 3-HYDROXYPYRAZOLES | BASF AG (DE) | 2003-09-17 | — | — | EP | disclosed |
| EP-1131298-B1 | METHOD FOR THE PRODUCTION OF 1-SUBSTITUTED 5-HYDROXYPYRAZOLES | BASF AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| US-20030109717-A1 | Preparation of substituted hydroxypyrazoles | GOTZ NORBERT (DE) | 2003-06-12 | — | — | US | disclosed |
| US-6472538-B1 | HIGH YIELD COUPLING, HYDROGENATION AND CYCLIZATION TO FORM CHEMICAL INTERMEDIATES FOR HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-29 | — | — | US | disclosed |
| US-6392058-B1 | REACTING AN ALKYL VINYL ETHER WITH PHOSGENE; FORMING ACYL CHLORIDE; ESTERIFICATION; REACTING WITH HYDRAZINE | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-21 | — | — | US | disclosed |
| US-6329530-B1 | REACTING ALKYL VINYL ETHER WITH PHOSGENE OR PHOSGENE DERIVATIVE TO FORM ACYL CHLORIDE DERIVATIVE; DEHYDROCHLORIANTING TO FORM 3-ALKOXYACRYLOYL CHLORIDE COMPOUND; REACTING WITH ALKYLHYDRAZINE | BASF AKTIENGESELLSCHAFT (DE) | 2001-12-11 | — | — | US | disclosed |
| US-5464860-A | Antiepileptic agents | NOVAPHARME (FR) | 1995-11-07 | — | — | US | disclosed |
| US-5258397-A | FOR TREATMENT OF EPILEPSY; SIDE EFFECT REDUCTION | NOVAPHARME (FR) | 1993-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174219-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 845/4885HCAR3 443/4885DAO 1404/4885 |
| US-10829438-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 845/4885HCAR3 443/4885DAO 1404/4885 |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 845/4885HCAR3 443/4885DAO 1404/4885 |
| US-20030109717-A1 | Preparation of substituted hydroxypyrazoles | CYC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | HCAR2 400/4885HCAR3 236/4885DAO 2333/4885 |
| US-10315984-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 845/4885HCAR3 443/4885DAO 1404/4885 |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | HCAR2 4489/4885HCAR3 4493/4885DAO 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.